| pembrolizumab based treatment |
| pembrolizumab plus SoC |
| non squamous cell - mNSCLC - L1 | |
| non squamous - mNSCLC - L1 - all population 3 | |
| non squamous - mNSCLC - L1 - PDL1 positive | |
| non squamous - mNSCLC - L1 - Wild Type (WT) 6 | |
Comparator:
vs placebo plus SoC;
Risk of bias:
low;
some concerns;
high;
NA;